PN6047
Peripheral Neuropathic Pain (Mechanical Allodynia)
Phase 2Active
Key Facts
Indication
Peripheral Neuropathic Pain (Mechanical Allodynia)
Phase
Phase 2
Status
Active
Company
About PharmNovo
PharmNovo is a clinical-stage biotech developing first-in-class, selective delta opioid receptor agonists (DORAs) for neuropathic and chronic pain, a market with significant unmet need. The company's lead asset, PN6047, has completed Phase I studies and received CTA approval in Spain for a Phase IIa proof-of-concept trial in peripheral neuropathic pain. PharmNovo is a private company preparing for mid-stage clinical development, leveraging a novel mechanism intended to avoid the addictive properties and severe side effects of traditional opioids. Its strategy targets a large patient population underserved by current therapies.
View full company profile